BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

554 related articles for article (PubMed ID: 11675833)

  • 1. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute and prolonged treatment with low-molecular-weight heparin therapy in patients with unstable coronary artery disease.
    Husted S; Kher A
    Ann Med; 2000 Dec; 32 Suppl 1():53-9. PubMed ID: 11209983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of acute coronary syndromes with low molecular weight heparin: TIMI 11A and 11B.
    Turpie AG
    Can J Cardiol; 1998 Aug; 14 Suppl E():20E-23E. PubMed ID: 9779029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low molecular weight heparins in the treatment of unstable angina.
    Ageno W; Turpie AG
    Minerva Cardioangiol; 2002 Dec; 50(6):643-51. PubMed ID: 12473984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role of low-molecular-weight heparin in acute coronary syndromes].
    Gharbi M; Barakett N; Lahidheb DH; Smiri Z; Fehri W; Azzouzi F; Rahal N; Mhenni H; Haouala H; Guediche M
    Tunis Med; 2002 Dec; 80(12):725-32. PubMed ID: 12664498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparins and unstable angina--current perspectives.
    Turpie AG
    Haemostasis; 1997; 27 Suppl 1():19-24. PubMed ID: 9439754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low molecular weight heparins in the management of unstable angina/non-Q-wave myocardial infarction.
    Cohen M
    Semin Thromb Hemost; 1999; 25 Suppl 3():113-21. PubMed ID: 10549726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of unstable angina with the low molecular weight heparins.
    Ageno W; Turpie AG
    Vasc Med; 2000; 5(4):217-23. PubMed ID: 11213233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies.
    Spinler SA; Inverso SM; Cohen M; Goodman SG; Stringer KA; Antman EM;
    Am Heart J; 2003 Jul; 146(1):33-41. PubMed ID: 12851605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dalteparin for acute coronary syndromes.
    O'Loughlin DC
    Heart Dis; 1999; 1(5):329-36. PubMed ID: 11720639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or non-Q wave myocardial infarction: FRAX.I.S. (FRAxiparine in Ischaemic Syndrome).
    Eur Heart J; 1999 Nov; 20(21):1553-62. PubMed ID: 10529323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enoxaparin and dalteparin in unstable angina: new indication. Enoxaparin: a reference treatment. Dalteparin: no better than unfractionated heparin.
    Prescrire Int; 1999 Jun; 8(41):77-80. PubMed ID: 10558446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of low-molecular-weight heparins in the management of patients with unstable angina pectoris and non-Q-wave acute myocardial infarction.
    Monrad ES
    Am J Cardiol; 2000 Apr; 85(8A):2C-9C. PubMed ID: 10793174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prior aspirin users with acute non-ST-elevation coronary syndromes are at increased risk of cardiac events and benefit from enoxaparin.
    Santopinto J; Gurfinkel EP; Torres V; Marcos E; Bozovich GE; Mautner B; McCabe CH; Antman EM
    Am Heart J; 2001 Apr; 141(4):566-72. PubMed ID: 11275921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antithrombotics and anticoagulants in coronary syndromes and stroke.
    Turpie AG
    Semin Thromb Hemost; 2000; 26 Suppl 1():79-83. PubMed ID: 11011811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-molecular-weight heparins in acute coronary syndrome: acquired results and new perspectives].
    Ugo F; Ardissino D
    G Ital Cardiol (Rome); 2006 Dec; 7(12):771-9. PubMed ID: 17294602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
    Nicolau JC; Cohen M; Montalescot G
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):440-5. PubMed ID: 19365279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of low molecular weight heparins in acute coronary syndromes: an interventionalist's perspective.
    Gulba D
    Semin Thromb Hemost; 1999; 25 Suppl 3():123-7. PubMed ID: 10549727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
    Nguyen-Ho P; Levine GN
    Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of antithrombotics for acute coronary syndromes in the emergency department: considerations and impact.
    Mukherjee D; Eagle KA
    Prog Cardiovasc Dis; 2007; 50(3):167-80. PubMed ID: 17976502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.